ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 6.270-6.620 for the period, compared to the consensus EPS estimate of 6.340. The company issued revenue guidance of $768.0 million-$793.0 million, compared to the consensus revenue estimate of $769.6 million.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. Finally, Guggenheim restated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Stock Down 7.3%

Shares of ANIP traded down $5.25 during mid-day trading on Friday, hitting $66.28. 756,687 shares of the company's stock were exchanged, compared to its average volume of 291,084. The company has a market cap of $1.44 billion, a PE ratio of -120.51 and a beta of 0.56. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $77.00. The company has a 50-day simple moving average of $66.86 and a 200 day simple moving average of $60.70. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million for the quarter, compared to analysts' expectations of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm's revenue for the quarter was up 43.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.82 EPS. On average, research analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares of the company's stock, valued at $5,526,799.20. This trade represents a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now owns 68,624 shares of the company's stock, valued at $4,131,164.80. This represents a 1.44% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,200 shares of company stock worth $197,792. Insiders own 11.10% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.